

CLIENT CODE : C000138394
CLIENT'S NAME AND ADDRESS :
 ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
 F-703, F-703, LADO SARAI, MEHRAULI
 SOUTH WEST DELHI
 NEW DELHI 110030
 DELHI INDIA
 8800465156

SRL Ltd
 S.K. Tower, Hari Niwas, LBS Marg
 THANE, 400602
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956
 Email : customercare.thane@srl.in

PATIENT NAME : MADHAVI S SAWARDEKAR PATIENT ID : **MADHF010663181**

ACCESSION NO : **0181WB001082** AGE : 59 Years SEX : Female

DRAWN : RECEIVED : 25/02/2023 09:22 REPORTED : 01/03/2023 16:39

REFERRING DOCTOR : SELF CLIENT PATIENT ID :

Test Report Status	Results	Biological Reference Interval	Units
--------------------	---------	-------------------------------	-------

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

BLOOD COUNTS, EDTA WHOLE BLOOD

HEMOGLOBIN (HB)	12.3	12.0 - 15.0	g/dL
METHOD : SLS- HEMOGLOBIN DETECTION METHOD			
RED BLOOD CELL (RBC) COUNT	4.53	3.8 - 4.8	mil/ μ L
METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION			
WHITE BLOOD CELL (WBC) COUNT	6.88	4.0 - 10.0	thou/ μ L
METHOD : FLUORESCENCE FLOW CYTOMETRY			
PLATELET COUNT	268	150 - 410	thou/ μ L
METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION			

RBC AND PLATELET INDICES

HEMATOCRIT (PCV)	39.4	36.0 - 46.0	%
METHOD : CUMULATIVE PULSE HEIGHT DETECTION METHOD			
MEAN CORPUSCULAR VOLUME (MCV)	87.0	83.0 - 101.0	fL
METHOD : CALCULATED FROM RBC & HCT			
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	27.2	27.0 - 32.0	pg
METHOD : CALCULATED FROM THE RBC & HGB			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	31.2	Low 31.5 - 34.5	g/dL
METHOD : CALCULATED FROM THE HGB & HCT			
RED CELL DISTRIBUTION WIDTH (RDW)	13.2	11.6 - 14.0	%
METHOD : CALCULATED FROM RBC SIZE DISTRIBUTION CURVE			
MENTZER INDEX	19.2		
MEAN PLATELET VOLUME (MPV)	10.1	6.8 - 10.9	fL
METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT			

WBC DIFFERENTIAL COUNT

NEUTROPHILS	49	40 - 80	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING			
LYMPHOCYTES	41	High 20 - 40	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING			
MONOCYTES	5	2 - 10	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING			
EOSINOPHILS	5	1 - 6	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING			
ABSOLUTE NEUTROPHIL COUNT	3.39	2.0 - 7.0	thou/ μ L
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING			



CLIENT CODE : C000138394
CLIENT'S NAME AND ADDRESS :
 ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
 F-703, F-703, LADO SARAI, MEHRAULI
 SOUTH WEST DELHI
 NEW DELHI 110030
 DELHI INDIA
 8800465156

SRL Ltd
 S.K. Tower, Hari Niwas, LBS Marg
 THANE, 400602
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956
 Email : customercare.thane@srl.in

PATIENT NAME : MADHAVI S SAWARDEKAR **PATIENT ID : MADHF010663181**

ACCESSION NO : **0181WB001082** AGE : 59 Years SEX : Female

DRAWN : RECEIVED : 25/02/2023 09:22 REPORTED : 01/03/2023 16:39

REFERRING DOCTOR : SELF CLIENT PATIENT ID :

Test Report Status	Final	Results	Biological Reference Interval	Units
ABSOLUTE LYMPHOCYTE COUNT		2.81	1.0 - 3.0	thou/ μ L
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
ABSOLUTE MONOCYTE COUNT		0.31	0.2 - 1.0	thou/ μ L
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
ABSOLUTE EOSINOPHIL COUNT		0.32	0.02 - 0.50	thou/ μ L
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
NEUTROPHIL LYMPHOCYTE RATIO (NLR)		1.2		
MORPHOLOGY				
RBC		NORMOCYTIC NORMOCHROMIC		
WBC		NORMAL MORPHOLOGY		
METHOD : MICROSCOPIC EXAMINATION				
PLATELETS		ADEQUATE		
ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD				
E.S.R		06	< 20	mm at 1 hr
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD				
HBA1C		6.4	High Non-diabetic Adult < 5.7 Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
METHOD : HPLC				
ESTIMATED AVERAGE GLUCOSE(EAG)		137.0	High < 116.0	mg/dL
METHOD : CALCULATED PARAMETER				
GLUCOSE FASTING, FLUORIDE PLASMA				
FBS (FASTING BLOOD SUGAR)		110	High Normal 75 - 99 Pre-diabetics: 100 - 125 Diabetic: > or = 126	mg/dL
METHOD : ENZYMATIC REFERENCE METHOD WITH HEXOKINASE				
GLUCOSE, POST-PRANDIAL, PLASMA				
PPBS(POST PRANDIAL BLOOD SUGAR)		93	70 - 139	mg/dL
METHOD : ENZYMATIC REFERENCE METHOD WITH HEXOKINASE				
LIPID PROFILE, SERUM				
CHOLESTEROL, TOTAL		222	High Desirable cholesterol level < 200 Borderline high cholesterol 200 - 239 High cholesterol > / = 240	mg/dL



CLIENT CODE : C000138394
CLIENT'S NAME AND ADDRESS :
 ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
 F-703, F-703, LADO SARAI, MEHRAULI
 SOUTH WEST DELHI
 NEW DELHI 110030
 DELHI INDIA
 8800465156

SRL Ltd
 S.K. Tower, Hari Niwas, LBS Marg
 THANE, 400602
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956
 Email : customercare.thane@srl.in

PATIENT NAME : MADHAVI S SAWARDEKAR PATIENT ID : **MADHF010663181**

ACCESSION NO : **0181WB001082** AGE : 59 Years SEX : Female

DRAWN : RECEIVED : 25/02/2023 09:22 REPORTED : 01/03/2023 16:39

REFERRING DOCTOR : SELF CLIENT PATIENT ID :

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

METHOD : ENZYMATIC COLORIMETRIC ASSAY
 TRIGLYCERIDES 139 Normal: < 150 mg/dL
 Borderline high: 150 - 199
 High: 200 - 499
 Very High: >= 500

METHOD : ENZYMATIC COLORIMETRIC ASSAY
 HDL CHOLESTEROL **38** **Low** Low HDL Cholesterol <40 mg/dL
 High HDL Cholesterol >= 60

METHOD : ENZYMATIC, COLORIMETRIC
 CHOLESTEROL LDL **156** **High** Adult levels: mg/dL
 Optimal < 100
 Near optimal/above optimal: 100-129
 Borderline high : 130-159
 High : 160-189
 Very high : = 190

METHOD : ENZYMATIC COLORIMETRIC ASSAY
 NON HDL CHOLESTEROL **184** **High** Desirable : < 130 mg/dL
 Above Desirable : 130 -159
 Borderline High : 160 - 189
 High : 190 - 219
 Very high : > / = 220
 < OR = 30.0

VERY LOW DENSITY LIPOPROTEIN CHOL/HDL RATIO 27.8 **High** Low Risk : 3.3 - 4.4 mg/dL
 Average Risk : 4.5 - 7.0
 Moderate Risk : 7.1 - 11.0
 High Risk : > 11.0

LDL/HDL RATIO **4.1** **High** 0.5 - 3.0 Desirable/Low Risk
 3.1 - 6.0 Borderline/Moderate Risk
 >6.0 High Risk

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL 0.36 Upto 1.2 mg/dL

METHOD : COLORIMETRIC DIAZO
 BILIRUBIN, DIRECT 0.20 < 0.30 mg/dL

BILIRUBIN, INDIRECT 0.16 0.1 - 1.0 mg/dL

TOTAL PROTEIN 6.8 6.0 - 8.0 g/dL

METHOD : COLORIMETRIC
 ALBUMIN 4.3 3.97 - 4.94 g/dL

METHOD : COLORIMETRIC
 GLOBULIN 2.5 2.0 - 3.5 g/dL

ALBUMIN/GLOBULIN RATIO 1.7 1.0 - 2.1 RATIO





CLIENT CODE : C000138394
CLIENT'S NAME AND ADDRESS :
 ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
 F-703, F-703, LADO SARAI, MEHRAULI
 SOUTH WEST DELHI
 NEW DELHI 110030
 DELHI INDIA
 8800465156

SRL Ltd
 S.K. Tower, Hari Niwas, LBS Marg
 THANE, 400602
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956
 Email : customercare.thane@srl.in

PATIENT NAME : MADHAVI S SAWARDEKAR PATIENT ID : **MADHF010663181**

ACCESSION NO : **0181WB001082** AGE : 59 Years SEX : Female

DRAWN : RECEIVED : 25/02/2023 09:22 REPORTED : 01/03/2023 16:39

REFERRING DOCTOR : SELF CLIENT PATIENT ID :

Test Report Status	Final	Results	Biological Reference Interval	Units
ASPARTATE AMINOTRANSFERASE (AST/SGOT)		17	< OR = 35	U/L
METHOD : UV ABSORBANCE				
ALANINE AMINOTRANSFERASE (ALT/SGPT)		29	< OR = 35	U/L
METHOD : UV ABSORBANCE				
ALKALINE PHOSPHATASE		103	35 - 104	U/L
METHOD : COLORIMETRIC				
GAMMA GLUTAMYL TRANSFERASE (GGT)		41	High 0 - 40	U/L
METHOD : ENZYMATIC, COLORIMETRIC				
LACTATE DEHYDROGENASE		165	125 - 220	U/L
METHOD : UV ABSORBANCE				
BLOOD UREA NITROGEN (BUN), SERUM				
BLOOD UREA NITROGEN		10	6 - 20	mg/dL
METHOD : ENZYMATIC ASSAY				
CREATININE, SERUM				
CREATININE		0.79	0.5 - 0.9	mg/dL
METHOD : COLORIMETRIC				
BUN/CREAT RATIO				
BUN/CREAT RATIO		12.66	8.0 - 15.0	
URIC ACID, SERUM				
URIC ACID		6.8	High 2.4 - 5.7	mg/dL
METHOD : ENZYMATIC COLORIMETRIC ASSAY				
TOTAL PROTEIN, SERUM				
TOTAL PROTEIN		6.8	6.0 - 8.0	g/dL
METHOD : COLORIMETRIC				
ALBUMIN, SERUM				
ALBUMIN		4.3	3.97 - 4.94	g/dL
METHOD : COLORIMETRIC				
GLOBULIN				
GLOBULIN		2.5	2.0 - 3.5	g/dL
ELECTROLYTES (NA/K/CL), SERUM				
SODIUM, SERUM		142	136 - 145	mmol/L
POTASSIUM, SERUM		4.73	3.5 - 5.1	mmol/L
CHLORIDE, SERUM		104	98 - 107	mmol/L
PHYSICAL EXAMINATION, URINE				
COLOR		PALE YELLOW		
APPEARANCE		CLEAR		



Scan to View Details



Scan to View Report



CLIENT CODE : C000138394
CLIENT'S NAME AND ADDRESS :
 ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
 F-703, F-703, LADO SARAI, MEHRAULI
 SOUTH WEST DELHI
 NEW DELHI 110030
 DELHI INDIA
 8800465156

SRL Ltd
 S.K. Tower, Hari Niwas, LBS Marg
 THANE, 400602
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956
 Email : customercare.thane@srl.in

PATIENT NAME : MADHAVI S SAWARDEKAR PATIENT ID : **MADHF010663181**

ACCESSION NO : **0181WB001082** AGE : 59 Years SEX : Female

DRAWN : RECEIVED : 25/02/2023 09:22 REPORTED : 01/03/2023 16:39

REFERRING DOCTOR : SELF CLIENT PATIENT ID :

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CHEMICAL EXAMINATION, URINE

PH	6.0	5.00 - 7.50	
SPECIFIC GRAVITY	1.015	1.010 - 1.030	
PROTEIN	NOT DETECTED	NOT DETECTED	
GLUCOSE	NOT DETECTED	NOT DETECTED	
KETONES	NOT DETECTED	NOT DETECTED	
BLOOD	NOT DETECTED	NOT DETECTED	
BILIRUBIN	NOT DETECTED	NOT DETECTED	
UROBILINOGEN	NORMAL	NORMAL	
NITRITE	NOT DETECTED	NOT DETECTED	
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	1-2	0-5	/HPF
EPITHELIAL CELLS	0-1	0-5	/HPF
CASTS	NOT DETECTED		
CRYSTALS	NOT DETECTED		
BACTERIA	NOT DETECTED	NOT DETECTED	
YEAST	NOT DETECTED	NOT DETECTED	

THYROID PANEL, SERUM

T3	117.0	Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester: 105.0 - 230.0 2nd Trimester: 129.0 - 262.0 3rd Trimester: 135.0 - 262.0	ng/dL
METHOD : ELECTROCHEMILUMINESCENCE			
T4	7.83	Non-Pregnant Women 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70	µg/dL
METHOD : ELECTROCHEMILUMINESCENCE			
TSH (ULTRASENSITIVE)	1.830	Non Pregnant Women 0.27 - 4.20 Pregnant Women 1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15	µIU/mL



Scan to View Details



Scan to View Report

CLIENT CODE : C000138394
CLIENT'S NAME AND ADDRESS :
 ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
 F-703, F-703, LADO SARAI, MEHRAULI
 SOUTH WEST DELHI
 NEW DELHI 110030
 DELHI INDIA
 8800465156

SRL Ltd
 S.K. Tower, Hari Niwas, LBS Marg
 THANE, 400602
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956
 Email : customercare.thane@srl.in

PATIENT NAME : MADHAVI S SAWARDEKAR PATIENT ID : **MADHF010663181**

ACCESSION NO : **0181WB001082** AGE : 59 Years SEX : Female

DRAWN : RECEIVED : 25/02/2023 09:22 REPORTED : 01/03/2023 16:39

REFERRING DOCTOR : SELF CLIENT PATIENT ID :

Test Report Status	Results	Biological Reference Interval	Units
--------------------	---------	-------------------------------	-------

METHOD : ELECTROCHEMILUMINESCENCE

PAPANICOLAOU SMEAR

TEST METHOD CONVENTIONAL GYNEC CYTOLOGY

METHOD : MICROSCOPIC EXAMINATION

SPECIMEN TYPE P 297/23

METHOD : MICROSCOPIC EXAMINATION

TWO UNSTAINED CERVICAL SMEARS RECEIVED

REPORTING SYSTEM 2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY

SPECIMEN ADEQUACY SATISFACTORY

METHOD : PAP STAIN & MICROSCOPIC EXAMINATION

MICROSCOPY THE SMEARS SHOW MANY PARABASAL CELLS , BASAL CELLS , FEW SUPERFICIAL SQUAMOUS CELLS, FEW INTERMEDIATE SQUAMOUS CELLS, OCCASIONAL SQUAMOUS METAPLASTIC CELLS, IN THE BACKGROUND OF MODERATE POLYMORPHS & NUMEROUS RBC'S.

METHOD : PAP STAIN

INTERPRETATION / RESULT NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY

METHOD : PAP STAIN & MICROSCOPIC EXAMINATION

- ATROPHY

METHOD : PAP STAIN & MICROSCOPIC EXAMINATION

ENDOMETRIAL CELLS (IN A WOMAN >= 45 YRS) ABSENT

METHOD : PAP STAIN & MICROSCOPIC EXAMINATION

Comments

PLEASE NOTE PAPANICOLAOU SMEAR STUDY IS A SCREENING PROCEDURE FOR CERVICAL CANCER WITH INHERENT FALSE NEGATIVE RESULTS HENCE SHOULD BE INTERPRETED WITH CAUTION. NO CYTOLOGICAL EVIDENCE OF HPV INFECTION IN THE SMEARS STUDIED. SMEARS WILL BE PRESERVED FOR 5 YEARS ONLY.

PHYSICAL EXAMINATION, STOOL

COLOUR SAMPLE NOT RECEIVED

METHOD : VISUAL

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE A

METHOD : GEL COLUMN AGGLUTINATION METHOD.

RH TYPE POSITIVE

METHOD : GEL COLUMN AGGLUTINATION METHOD.

XRAY-CHEST



Scan to View Details



Scan to View Report

CLIENT CODE : C000138394
CLIENT'S NAME AND ADDRESS :
 ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
 F-703, F-703, LADO SARAI, MEHRAULI
 SOUTH WEST DELHI
 NEW DELHI 110030
 DELHI INDIA
 8800465156

SRL Ltd
 S.K. Tower, Hari Niwas, LBS Marg
 THANE, 400602
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956
 Email : customercare.thane@srl.in

PATIENT NAME : MADHAVI S SAWARDEKAR **PATIENT ID : MADHF010663181**

ACCESSION NO : **0181WB001082** AGE : 59 Years SEX : Female

DRAWN : RECEIVED : 25/02/2023 09:22 REPORTED : 01/03/2023 16:39

REFERRING DOCTOR : SELF CLIENT PATIENT ID :

Test Report Status	Results	Biological Reference Interval	Units
--------------------	---------	-------------------------------	-------

IMPRESSION AORTIC KNUCKLE CALCIFICATION WITH UNFOLDING OF AORTA (AGE RELATED)
MILD HILAR PROMINENCE NOTED ON RIGHT SIDE.

TMT OR ECHO
 TMT OR ECHO 2D ECHO :- CONCENTRIC LVH.

ECG
 ECG WITHIN NORMAL LIMITS

MAMOGRAPHY (BOTH BREASTS)
 MAMOGRAPHY BOTH BREASTS SONO BREAST :- NORMAL

MEDICAL HISTORY
 RELEVANT PRESENT HISTORY HYPERTENSION SINCE 4 YEARS.
C/O JOINT PAINS ON & OFF ON PHYSIOTHERAPY
 RELEVANT PAST HISTORY NOT SIGNIFICANT
 RELEVANT PERSONAL HISTORY MARRIED / 2 CHILD / MIXED DIET / NO ALLERGIES / NO SMOKING / NO ALCOHOL.
 MENSTRUAL HISTORY (FOR FEMALES) MENOPAUSAL
 OBSTETRIC HISTORY (FOR FEMALES) 1 LSCS 1 FTND,A0,L2
 LCB (FOR FEMALES) 30 YEARS BACK.
 RELEVANT FAMILY HISTORY FATHER :- DIABETES
 HISTORY OF MEDICATIONS TAB :- TELMA

ANTHROPOMETRIC DATA & BMI
 HEIGHT IN METERS 1.51 mts
 WEIGHT IN KGS. 76 Kgs
 BMI 33
BMI & Weight Status as follows: kg/sqmts
 Below 18.5: Underweight
 18.5 - 24.9: Normal
 25.0 - 29.9: Overweight
 30.0 and Above: Obese

GENERAL EXAMINATION
 MENTAL / EMOTIONAL STATE NORMAL
 PHYSICAL ATTITUDE NORMAL
 GENERAL APPEARANCE / NUTRITIONAL STATUS OBESE
 BUILT / SKELETAL FRAMEWORK AVERAGE
 FACIAL APPEARANCE NORMAL
 SKIN NORMAL
 UPPER LIMB NORMAL



Scan to View Details



Scan to View Report

CLIENT CODE : C000138394
CLIENT'S NAME AND ADDRESS :
 ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
 F-703, F-703, LADO SARAI, MEHRAULI
 SOUTH WEST DELHI
 NEW DELHI 110030
 DELHI INDIA
 8800465156

SRL Ltd
 S.K. Tower, Hari Niwas, LBS Marg
 THANE, 400602
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956
 Email : customercare.thane@srl.in

PATIENT NAME : MADHAVI S SAWARDEKAR **PATIENT ID : MADHF010663181**

ACCESSION NO : **0181WB001082** AGE : 59 Years SEX : Female

DRAWN : RECEIVED : 25/02/2023 09:22 REPORTED : 01/03/2023 16:39

REFERRING DOCTOR : SELF CLIENT PATIENT ID :

Test Report Status	Results	Biological Reference Interval	Units
--------------------	---------	-------------------------------	-------

LOWER LIMB	NORMAL		
NECK	NORMAL		
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDER		
THYROID GLAND	NOT ENLARGED		
CAROTID PULSATION	NORMAL		
BREAST (FOR FEMALES)	NORMAL		
TEMPERATURE	NORMAL		
PULSE	78/MIN.REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID BRUIT		
RESPIRATORY RATE	NORMAL		
CARDIOVASCULAR SYSTEM			
BP	110/70 MM HG (SUPINE)		mm/Hg
PERICARDIUM	NORMAL		
APEX BEAT	NORMAL		
HEART SOUNDS	NORMAL		
MURMURS	ABSENT		
RESPIRATORY SYSTEM			
SIZE AND SHAPE OF CHEST	NORMAL		
MOVEMENTS OF CHEST	SYMMETRICAL		
BREATH SOUNDS INTENSITY	NORMAL		
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)		
ADDED SOUNDS	ABSENT		
PER ABDOMEN			
APPEARANCE	NORMAL		
VENOUS PROMINENCE	ABSENT		
LIVER	NOT PALPABLE		
SPLEEN	NOT PALPABLE		
HERNIA	ABSENT		
CENTRAL NERVOUS SYSTEM			
HIGHER FUNCTIONS	NORMAL		
CRANIAL NERVES	NORMAL		
CEREBELLAR FUNCTIONS	NORMAL		
SENSORY SYSTEM	NORMAL		
MOTOR SYSTEM	NORMAL		



CLIENT CODE : C000138394
CLIENT'S NAME AND ADDRESS :
 ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
 F-703, F-703, LADO SARAI, MEHRAULI
 SOUTH WEST DELHI
 NEW DELHI 110030
 DELHI INDIA
 8800465156

SRL Ltd
 S.K. Tower, Hari Niwas, LBS Marg
 THANE, 400602
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956
 Email : customercare.thane@srl.in

PATIENT NAME : MADHAVI S SAWARDEKAR PATIENT ID : **MADHF010663181**

ACCESSION NO : **0181WB001082** AGE : 59 Years SEX : Female

DRAWN : RECEIVED : 25/02/2023 09:22 REPORTED : 01/03/2023 16:39

REFERRING DOCTOR : SELF CLIENT PATIENT ID :

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

REFLEXES		NORMAL		
MUSCULOSKELETAL SYSTEM				
SPINE		NORMAL		
JOINTS		NORMAL		
BASIC EYE EXAMINATION				
CONJUNCTIVA		NORMAL		
EYELIDS		NORMAL		
EYE MOVEMENTS		NORMAL		
CORNEA		NORMAL		
DISTANT VISION RIGHT EYE WITHOUT GLASSES		REDUCED VISUAL ACUITY 6/12		
DISTANT VISION LEFT EYE WITHOUT GLASSES		REDUCED VISUAL ACUITY 6/9		
NEAR VISION RIGHT EYE WITHOUT GLASSES		REDUCED VISUAL ACUITY N/24		
NEAR VISION LEFT EYE WITHOUT GLASSES		REDUCED VISUAL ACUITY N/24		
NEAR VISION RIGHT EYE WITH GLASSES		WITHIN NORMAL LIMIT		
NEAR VISION LEFT EYE WITH GLASSES		WITHIN NORMAL LIMIT		
COLOUR VISION		NORMAL		
SUMMARY				
RELEVANT HISTORY		NOT SIGNIFICANT		
RELEVANT GP EXAMINATION FINDINGS		OBESE :- BMI 33		
REMARKS / RECOMMENDATIONS		OPHTHALMOLOGY CONSULT FOR REDUCED VISUAL ACUITY WEIGHT LOSS -LOW FAT,LOW CALORIE, LOW CARBOHYDRATE, HIGH FIBRE DIET. REGULAR EXERCISE.REGULAR WALK FOR 30-40 MIN DAILY. REPEAT LIPID PROFILE, BLOOD SUGAR AFTER 3 MONTHS OF DIET AND EXERCISE. AVOID HIGH QUALITY PROTEIN DIET. DAILY EXPOSURE TO SUNLIGHT FOR 20 MIN. ADD LOW FAT DAIRY PRODUCTS TO DAILY DIET. VITAMIN D SUPPLEMENTS PHYSICIAN CONSULT FOR THE SAME. TO DO 25)OH)VITAMIN D.		

Interpretation(s)
 BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.
 RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.



Scan to View Details



Scan to View Report

CLIENT CODE : C000138394
CLIENT'S NAME AND ADDRESS :
 ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
 F-703, F-703, LADO SARAI, MEHRAULI
 SOUTH WEST DELHI
 NEW DELHI 110030
 DELHI INDIA
 8800465156

SRL Ltd
 S.K. Tower, Hari Niwas, LBS Marg
 THANE, 400602
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956
 Email : customercare.thane@srl.in

PATIENT NAME : MADHAVI S SAWARDEKAR PATIENT ID : **MADHF010663181**

ACCESSION NO : **0181WB001082** AGE : 59 Years SEX : Female

DRAWN : RECEIVED : 25/02/2023 09:22 REPORTED : 01/03/2023 16:39

REFERRING DOCTOR : SELF CLIENT PATIENT ID :

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculitides, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR (>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr (62 if anemic) and in second trimester (0-70 mm/hr (95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythemia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs (Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (Sickle Cells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

GLYCOSYLATED HEMOGLOBIN (HbA1c), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2. Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to mg/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months.

3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addition are reported to interfere with some assay methods, falsely increasing results.

4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate platform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in: Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in : Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g. galactosemia), Drugs-insulin, ethanol, propranolol, sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.



Scan to View Details



Scan to View Report

CLIENT CODE : C000138394
CLIENT'S NAME AND ADDRESS :
 ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
 F-703, F-703, LADO SARAI, MEHRAULI
 SOUTH WEST DELHI
 NEW DELHI 110030
 DELHI INDIA
 8800465156

SRL Ltd
 S.K. Tower, Hari Niwas, LBS Marg
 THANE, 400602
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956
 Email : customercare.thane@srl.in

PATIENT NAME : MADHAVI S SAWARDEKAR PATIENT ID : **MADHF010663181**

ACCESSION NO : **0181WB001082** AGE : 59 Years SEX : Female

DRAWN : RECEIVED : 25/02/2023 09:22 REPORTED : 01/03/2023 16:39

REFERRING DOCTOR : SELF CLIENT PATIENT ID :

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM- Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM- Higher than normal level may be due to:

- Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM- Causes of Increased levels: Dietary (High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome **Causes of decreased levels:** Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM- is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-
 Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. **Low blood albumin levels (hypoalbuminemia) can be caused by:** Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD- Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A, B, O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

MEDICAL

HISTORY-*****
 THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.



Scan to View Details



Scan to View Report

CLIENT CODE : C000138394
CLIENT'S NAME AND ADDRESS :
 ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
 F-703, F-703, LADO SARAI, MEHRAULI
 SOUTH WEST DELHI
 NEW DELHI 110030
 DELHI INDIA
 8800465156

SRL Ltd
 S.K. Tower, Hari Niwas, LBS Marg
 THANE, 400602
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956
 Email : customercare.thane@srl.in

PATIENT NAME : MADHAVI S SAWARDEKAR PATIENT ID : **MADHF010663181**

ACCESSION NO : **0181WB001082** AGE : 59 Years SEX : Female

DRAWN : RECEIVED : 25/02/2023 09:22 REPORTED : 01/03/2023 16:39

REFERRING DOCTOR : SELF CLIENT PATIENT ID :

Test Report Status	Final	Results	Units
--------------------	-------	---------	-------

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ULTRASOUND ABDOMEN
ULTRASOUND ABDOMEN
 GRADE I FATTY LIVER

****End Of Report****
 Please visit www.srlworld.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form
5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
8. Test results cannot be used for Medico legal purposes.
9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

SRL Limited
 Fortis Hospital, Sector 62, Phase VIII,
 Mohali 160062



Scan to View Details



Scan to View Report